European Commission fines Alchem for participating in API cartel

The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle

Faron publishes study highlighting role of sClever-1 as immune blocker in cancer

The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells

atai and Beckley Psytech announce positive Phase 2b results for treatment-resistant depression

atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.

argenx advances clinical development of agonist antibody for myasthenic syndromes

ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept

Sigachi updates on fire accident at its Pashamylaram Facility, Telangana

The company has confirmed that the deceased are 39

Zota Health Care expands Davaindia network to 1,760 operational stores

Surpassing 1,000 Company Owned Company Operated stores

Lupin launches nasal spray in US

Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals

Yatharth Hospitals names Ashutosh Kumar Jha as Group Chief – Strategy, M&A, and Investor Relations

Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million to strengthen US footprint

The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market

Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy

ART-123 is a recombinant human thrombomodulin approved in Japan in 2008